Merrimack Pharmaceuticals Director Buys $97,350 in Stock (MACK)
Merrimack Pharmaceuticals (NASDAQ:MACK) Director Michael E. Porter bought 15,000 shares of the stock on the open market in a transaction dated Friday, May 16th. The stock was purchased at an average cost of $6.49 per share, for a total transaction of $97,350.00. Following the acquisition, the director now directly owns 535,865 shares of the company’s stock, valued at approximately $3,477,764. The transaction was disclosed in a filing with the SEC, which is available at this link.
MACK has been the subject of a number of recent research reports. Analysts at Mizuho raised their price target on shares of Merrimack Pharmaceuticals from $12.00 to $13.00 in a research note on Friday, May 2nd. Separately, analysts at Cowen and Company upgraded shares of Merrimack Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 1st. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Merrimack Pharmaceuticals from $9.00 to $15.00 in a research note on Thursday, May 1st. One investment analyst has rated the stock with a hold rating and two have assigned a buy rating to the company. Merrimack Pharmaceuticals has an average rating of “Buy” and a consensus target price of $12.00.
Merrimack Pharmaceuticals (NASDAQ:MACK) traded up 2.69% on Friday, hitting $6.87. The stock had a trading volume of 1,532,960 shares. Merrimack Pharmaceuticals has a 1-year low of $2.05 and a 1-year high of $7.65. The stock has a 50-day moving average of $5.43 and a 200-day moving average of $4.88. The company’s market cap is $710.4 million.
Merrimack Pharmaceuticals (NASDAQ:MACK) last released its earnings data on Thursday, May 1st. The company reported ($0.27) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.30) by $0.03. The company had revenue of $13.03 million for the quarter, compared to the consensus estimate of $11.93 million. Analysts expect that Merrimack Pharmaceuticals will post $-1.16 EPS for the current fiscal year.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.